Hernias

Boswellia serrata was used as a key ingredient in a clinical RCT nutraceutical formulation specifically for TMD patients, showing significant pain reduction over 40 days. Boswellic acids inhibit 5-lipoxygenase and reduce pro-inflammatory leukotriene synthesis. It has been cited alongside glucosamine and palmitoylethanolamide in TMD nutraceutical research reviews.

Boswellic acids are the active constituents of Boswellia serrata responsible for 5-LOX inhibition and anti-inflammatory effects studied in joint conditions including TMJ-relevant osteoarthritis. They are included in formulations tested for TMD and are cited in nutraceutical reviews for orofacial joint pain. Their mechanism of reducing leukotriene production is directly applicable to TMJ inflammatory pathways.

Cannabidiol (CBD) has been tested in multiple RCTs for TMJ and orofacial pain. A double-blind trial found topical CBD cream reduced masseter muscle pain VAS scores by 70.2% versus 9.81% for placebo at 14 days. A separate RCT showed intraoral CBD formulations significantly reduced TMD-related pain, muscle tension, and bruxism activity. A 2025 systematic review confirmed CBD's analgesic potential in TMD.

Chondroitin sulfate has been studied alongside glucosamine in multiple RCTs for TMJ osteoarthritis and internal derangement. A 2022 meta-analysis of three RCTs found qualitative reductions in TMJ pain, joint noise, and synovial inflammatory biomarkers, plus improved maximum mouth opening. The combination is considered effective and safe for symptomatic TMD per a 2022 PubMed systematic review.

Curcumin has been studied specifically in TMJ osteoarthritis in both in vitro and animal models, demonstrating inhibition of cartilage-degrading enzymes (MMP-1, MMP-3, MMP-9, MMP-13), inflammatory mediators (IL-6, iNOS, COX-2), and protection of TMJ chondrocytes via the Nrf2/ARE pathway. It is cited in TMJ/TMD supplement literature as an anti-inflammatory agent.

Multiple randomized controlled trials and a systematic review (2023, Int J Mol Sci) have examined oral glucosamine specifically for TMJ osteoarthritis. One RCT found glucosamine sulfate plus chondroitin reduced pain and improved maximum mouth opening versus tramadol. A pilot double-blind RCT showed improvements in pain, TMJ tenderness, and joint sounds compared with placebo.

Hyaluronic acid (HA) intra-articular injections are one of the most studied interventions for TMJ disorders. A 2010 systematic review of 19 studies reported decreased pain across all protocols. A 2016 RCT found HA injections superior to splint therapy for pain, maximum mouth opening, and quality of life at 6 months. A 2025 systematic review confirmed HA improves TMJ biomechanics.

L-Tryptophan was incorporated in a specifically designed TMD nutraceutical RCT formulation (with Boswellia, magnesium, vitamins B2 and D3) that demonstrated significant pain reduction over 40 days in TMD patients. As the serotonin precursor, it addresses central pain sensitization and bruxism-related muscle hyperactivity relevant to TMD pathophysiology.

Magnesium has been investigated in both clinical and preclinical contexts for TMJ and myogenic TMD. A randomized clinical study demonstrated local magnesium injection effectively reduced myofascial trigger point pain and improved mouth opening in masticatory muscles. Magnesium deficiency is linked to bruxism and orofacial pain through NMDA receptor modulation.

MSM was included in a randomized clinical trial specifically for TMJ osteoarthritis (alongside glucosamine and chondroitin), and has documented anti-inflammatory properties relevant to joint pain. An independent 2023 RCT in knee OA demonstrated MSM improved joint conditions over 12 weeks. It appears in TMJ supplement guidance from physical therapy and dental sources.

Omega-3 fatty acids have demonstrated anti-inflammatory effects specific to TMJ inflammation in preclinical models. Systemic administration reduced TMJ damage and proinflammatory cytokines (IL-1β, TNF-α) in animal TMJ arthritis models. They are consistently recommended in TMJ supplement guidance as anti-inflammatory agents for joint pain management.

Palmitoylethanolamide (PEA) has been directly tested in a triple-blind RCT for TMJ inflammatory pain, outperforming ibuprofen in pain reduction and mouth opening improvement. PEA acts via autacoid local inflammation antagonism, modulating mast cells and the endocannabinoid system. It is recognized in nutraceutical reviews specifically for TMJ/TMD management.

Clinical studies have linked low vitamin B12 serum levels to TMJ osteoarthritis severity, specifically correlating with condylar erosion. A 2024 study of 90 bilateral TMJ-OA patients found 82.2% had low B12 levels. B12 deficiency-related neuropathic pain and muscle dysfunction are recognized as exacerbating factors in TMD.

A systematic review (2022) found vitamin D serum levels are consistently lower in TMD patients, and a retrospective multi-center cohort study found deficient 25(OH)D levels associated with 50% increased TMD incidence risk. A double-blind placebo-controlled RCT found vitamin D supplementation plus splint therapy significantly improved comfort mouth opening, maximum mouth opening, and pain scores in vitamin D-deficient TMD patients.

Vitamin D3 (cholecalciferol) is the specific form studied in a double-blind RCT for vitamin D-deficient TMD patients in combination with splint therapy, showing significant improvements in mouth opening and pain scores. It was also included in a TMD nutraceutical RCT formulation (Boswellia, magnesium, tryptophan, B2, D3). Deficiency is associated with higher TMD incidence in cohort studies.